Log in
Enquire now
‌

US Patent 7459472 Aryl and heteroaryl compounds, compositions, and methods of use

Patent 7459472 was granted and assigned to TransTech Pharma on December, 2008 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Current Assignee
TransTech Pharma
TransTech Pharma
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
7459472
Date of Patent
December 2, 2008
Patent Application Number
10913216
Date Filed
August 6, 2004
Patent Citations Received
‌
US Patent 11944631 Combination therapies
0
‌
US Patent 11939333 Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
0
Patent Primary Examiner
‌
Rei Tsang Shiao
Patent abstract

This invention provides aryl and heteroaryl compounds of Formula (I) as described herein, and methods of their preparation. Also provided are pharmaceutical compositions made with the compounds of Formula (I) and methods for making such compositions. Compounds of Formula (I) may be useful for treating viral infections including orthopox viruses, either alone or in combination with other therapeutic agents.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 7459472 Aryl and heteroaryl compounds, compositions, and methods of use

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.